pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ELI LILLY CO · news · pharmadog
← back to ELI LILLY CO
News mentioning ELI LILLY CO
625
stories
7d
Health insurance premiums jump 9%, and more Americans don’t have access to coverage
stat
7d
STAT+: Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction
stat
8d
Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal
biopharma dive
8d
Drug prices climb past $250K as US patients balk at the pharmacy
biospace
8d
Novo’s CagriSema achieves 25% weight loss in women, driven by younger patients
biospace
9d
Lilly’s retatrutide creeps closer to market for sleep apnea
endpoints
9d
The 6 biggest crossover rounds in biopharma history
biospace
9d
Biotech reverse mergers rebound to highest level since 2021 as PIPEs flood market: report
fiercebiotech
9d
STAT+: A bipartisan group of lawmakers urges the FDA to close a peptide loophole
stat
9d
STAT+: Pharmalittle: We’re reading about drug launch prices, an AstraZeneca AI deal, and more
stat
9d
Lilly puts $1.1B on the line for Hong Kong biotech’s AI drug delivery platform
biospace
9d
Gilead’s ‘highly competitive’ mid-stage ulcerative colitis data ‘validate’ I&I push
biospace
10d
EyePoint's Phase 3 failure; Lilly's China drug delivery deal
endpoints
10d
Novartis ends mid-stage Fabhalta study in lupus, insists no efficacy or safety issues
biospace
10d
Veradermics’ minoxidil pill improves hair coverage in men in Phase 3
biospace
10d
Lilly partners with Hong Kong's Metis in $1.1B deal to bolster AI nanoparticle discovery
fiercebiotech
11d
ESMO: Lilly touts 79% ADC response rate in competitive ovarian cancer space
fiercebiotech
11d
Should amylin have been obesity therapeutics’ primary target from the start?
biospace
13d
CHMP endorses Eli Lilly’s GLP-1 pill and three other new drugs
endpoints
13d
Lilly interested in ibogaine investments, its neuro leader says
endpoints
13d
Biogen-backed Estuary nabs $93M for kidney disease gene therapy
biopharma dive
14d
AstraZeneca bulks up MASH, cardio work in up to $1.5B AI partnership with insitro
biospace
14d
Estuary flows out of stealth with $103M to propel kidney disease gene therapies into clinic
fiercebiotech
15d
AstraZeneca inks $1.5B insitro deal for AI-enabled target discovery of liver, heart disease drugs
fiercebiotech
15d
Iambic goes public with $150M IPO to accelerate clinical development of oncology pipeline
fiercebiotech
15d
Verastem cancer drug shows early promise in small study
biopharma dive
15d
‘Pharma bro’ Shkreli runs afoul of court’s lifetime pharma ban
biospace
15d
Zealand pens up to $1.2B deal with Generate for AI-designed obesity, metabolic drugs
biospace
15d
Verdiva ends mid-stage study of oral GLP-1 amid ‘market evolution’
biospace
15d
Deep-pocketed Verdiva axes GLP-1 switching trial over ‘market evolution’
fiercebiotech
← prev
page 2 of 21
next →
